CAMBRIDGE, Mass., Oct. 4 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the election of
Jeffrey M. Leiden, M.D., Ph.D., to its Board of Directors. Dr. Leiden, a
Managing Director at Clarus Ventures, a life sciences venture capital firm,
has a distinguished career of more than 20 years of experience in the
biomedical and pharmaceutical sectors. Prior to joining Clarus, Dr. Leiden
served as President and Chief Operating Officer of the Global
Pharmaceutical Business of Abbott Laboratories.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
"It is a pleasure to have Dr. Leiden join the Millennium Board of
Directors," said Deborah Dunsire, M.D., President and Chief Executive
Officer, Millennium. "We believe his diverse pharmaceutical and scientific
experience will enable him to help guide our continued growth and success
in our mission of delivering vital medicines to patients."
Prior to joining Abbott Laboratories in 2000, Dr. Leiden was the Elkan
R. Blout Professor of Biological Sciences at Harvard School of Public
Health, as well as Professor of Medicine at Harvard Medical School. Before
his career at Harvard, he served as Professor of Medicine and Pathology and
Chief of Cardiology at the University of Chicago, School of Medicine. Dr.
Leiden has also co-founded several biotechnology firms.
"I'm delighted to join Millennium's Board of Directors and begin
supporting Millennium's management in continuing to build a leading
biopharmaceutical company," said Dr. Leiden. "I look forward to utilizing
my experiences and knowledge to further the Company's success and deliver
important drugs to patients in need."
Dr. Leiden earned both his medical degree and Ph.D. from the University
of Chicago as well as an honorary M.A. from Harvard University. He is an
elected member of the American Academy of Arts and Sciences and the
Institute of Medicine of the National Academy of Sciences.
Dr. Leiden joins the Board as an independent director. His appointment
brings the number of Millennium Board members to ten.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company
based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has
a robust clinical development pipeline of product candidates. Millennium's
research, development and commercialization activities are focused in two
therapeutic areas: oncology and inflammation. By applying its knowledge of
the human genome, understanding of disease mechanisms and industrialized
drug discovery platform, Millennium is developing an exciting pipeline of
innovative product candidates. Millennium's website is
http://www.millennium.com.
This press release contains "forward-looking statements," including
statements about the Company's growth and development of products. Various
important risks may cause the Company's actual results to differ materially
from the results indicated by these forward-looking statements, including:
adverse results in its drug discovery and clinical development programs;
failure to obtain patent protection for its discoveries; commercial
limitations imposed by patents owned or controlled by third parties; the
Company's dependence upon strategic alliance partners to develop and
commercialize products and services based on its work; difficulties or
delays in obtaining regulatory approvals to market products and services
resulting from its development efforts; product withdrawals; competitive
factors; difficulties or delays in manufacturing the Company's products;
government and third-party reimbursement rates; the commercial success of
VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue
consistent with internal forecasts; and the requirement for substantial
funding to conduct research and development and to expand commercialization
activities. For a further list and description of the risks and
uncertainties the Company faces, see the reports it has filed with the
Securities and Exchange Commission. The Company disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Editors' Note: This press release is also available under the Media
section of the Company's website at: http://www.millennium.com.
Contacts:
Jennifer Snyder (media) Kyle Kuvalanka (investors)
(617) 444-1439 (617) 761-4734
SOURCE Millennium Pharmaceuticals, Inc.
 back to top
Related links:
http://www.millennium.com
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
http://www.prnewswire.com/comp/114562.html /
CONTACT:
Media, Jennifer Snyder, +1-617-444-1439, or
Investors, Kyle Kuvalanka, +1-617-761-4734, both of Millennium
Pharmaceuticals, Inc.
|
